항생제 내성 진단 시장 전망 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Antimicrobial Resistance Diagnostics Market was valued at USD 4.4 billion in 2023 and is projected to expand at a CAGR of over 6.3% from 2024 to 2032. The market is driven by the growing incidence of antibiotic-resistant infections, the increasing demand for personalized treatments, and significant advancements in diagnostic technologies.

The market is divided into two main product categories: instruments & consumables and kits & reagents. In 2023, the kits & reagents segment led the market with a value of USD 2.8 billion. These diagnostic kits and reagents play a crucial role in the rapid and accurate identification of antibiotic-resistant bacterial strains. Early detection of resistance is essential for ensuring effective treatment regimens and reducing the overuse of antibiotics, which is a primary factor in the development of resistance. Global and regional efforts, such as initiatives from health organizations, are further driving the demand for AMR diagnostic tools.

When examining the technologies used in antimicrobial resistance diagnostics, the market is segmented into microbiology culture, immunoassay, PCR, next-generation sequencing (NGS), mass spectrometry, rapid & point-of-care diagnostics, and other technologies. The microbiology culture segment held a significant share of 31.1% in 2023. Technological advancements in microbial culture have greatly improved the speed, accuracy, and specificity of identifying resistant strains. The automation of culture systems has notably reduced the time required for diagnostics, making culture-based methods more reliable in detecting antibiotic-resistant bacteria, which is expected to further propel market growth.

U.S. antimicrobial resistance diagnostic market is projected to grow at a CAGR of 6.2%, reaching USD 3.1 billion by 2032. U.S. government initiatives focused on combating antibiotic resistance, such as the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), have contributed to the expansion of AMR diagnostic capabilities. These initiatives support advancements in diagnostic technologies and provide funding for research and development in the field. Additionally, the U.S. Department of Health and Human Services has committed substantial investments to enhance AMR diagnostics, research, and the development of novel antibiotics, further boosting market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of drug-resistant infection
    • 3.2.1.2 Advancement in diagnostic technology
    • 3.2.1.3 Rising awareness and training programs in healthcare facilities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High development and implementation cost
    • 3.2.2.2 Competition from alternative solutions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Technology landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Kits & reagents
• 5.3 Instruments & consumables

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Microbiology culture
• 6.3 Immunoassay
• 6.4 Polymerase chain reaction (PCR)
• 6.5 Next generation sequencing (NGS)
• 6.6 Mass spectrometry
• 6.7 Rapid & point of care
• 6.8 Other technologies

Chapter 7 Market Estimates and Forecast, By Pathogen Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Drug-resistant streptococcus pneumoniae (DRSP)
• 7.3 Drug-resistant campylobacter (DRC)
• 7.4 Clostridium difficile (CD)
• 7.5 Drug-resistant neisseria gonorrhoeae (DRNG)
• 7.6 Other pathogen types

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals & clinics
• 8.3 Diagnostic laboratories
• 8.4 Pharmaceutical & biotechnology companies
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Accelerated Diagnostics, USA
• 10.3 Alifax
• 10.4 Bio-Rad Laboratories
• 10.5 BioMerieux
• 10.6 Beckman Coulter
• 10.7 Becton, Dickinson and Company
• 10.8 F. Hoffmann-La Roche
• 10.9 GeneFluidics
• 10.10 Molsid
• 10.11 Thermo Fisher Scientific
• 10.12 Vela Diagnostics